Insights

Insights_final

Our Promidian consultants bring you insight on some of today’s pressing industry issues.

PharmaVoice The Radical Implications of Indication-Specific Pricing

radical implications

A major change is under way that has the potential to impact the entire process of developing, pricing, and selling pharmaceuticals—the advent of indication-specific pricing. This paper provides context to this important change, highlights some of the implications about which biopharma companies should be aware, and leaves you with a framework for raising and addressing pertinent questions across the biopharma value chain.
PharmaVoice The Radical Implications of Indication-Specific Pricing

Industry Issue Brief  Buying into Biosimilars: An Analysis of US Payer Views on Biosimilar Products

buying-into-biosimilars-button_new-3

As biosimilars enter the US market, payers hold enormous power to drive uptake, should they elect to employ preferential handling of biosimilars over the originator brands. Payers’ views on these new, potentially more cost-effective treatment alternatives should be top of mind for any manufacturer with a stake in this market. Through in-depth research with payers, Promidian has uncovered key decision-making factors and considerations of strategic value both for manufacturers looking to launch new biosimilar products as well as those preparing for biosimilar competition.
Buying into Biosimilars: An Analysis of US Payer Views on Biosimilar Products

PharmaVoice Don’t Poke the Bear: The Effect of Pharmaceutical Pricing on Perception and Future Innovation

Don't Poke the Bear Button

Aggressive pharmaceutical pricing strategies have recently grabbed headlines. Whether these strategies are justified or even successful is not the point. Rather, what is important is the negative public perception that significant price hikes create for the industry as a whole. In this climate, the industry needs to do a better job of talking about how prices are set and how that money is invested—otherwise we risk losing control of how we price our products and operate our businesses.
Don't Poke the Bear: The Effect of Pharmaceutical Pricing on Perception and Future Innovation

Pharmaceutical Executive Precision Medicine’s March to Market: “Pairing” for Success

Precision Medicine

With the recent wave of targeted therapy approvals and more biomarker-driven treatments on the horizon, properly commercializing biopharma drugs paired with a companion diagnostic can be a competitive differentiator. As recently published in Pharmaceutical Executive, Promidian experts offer four “can’t miss” strategies for successfully managing the development, launch, and commercialization of Rx-CDx pairings.
Precision Medicine’s March to Market: “Pairing” for Success

Pharmaceutical Executive Roundtable of Biopharma Industry Leaders Offers Insights on Market Access Challenges

F6F9276C-42E7-46E6-AE42-7C477492329E

Promidian participated in a feature roundtable hosted by Pharmaceutical Executive to discuss how market access dynamics are likely to evolve over the next few years and the implications of this evolution for biopharma companies. The magazine featured a recap of the highlights of the panel discussion.
Roundtable on Market Access

A Review of the FDA’s Draft Guidance on Biosimilars

12

The Biologics Price Competition and Innovation Act of 2009—enacted in March 2010 as part of the Patient Protection and Affordable Care Act—laid the foundation for an abbreviated approval pathway for biosimilars in the United States. However, the healthcare reform legislation left specific details of the approval pathway for biosimilars to the discretion of the US Food and Drug Administration (FDA), including regulatory processes and clinical trial requirements. As a result, industry stakeholders have been eagerly awaiting additional guidance.
A Review of the FDAs Draft Guidance on Biosimilars

The Patient-Centered Medical Home: An Emerging Health Care Delivery Model

6

Fundamental changes are being implemented in the healthcare industry at an accelerated rate. It is critical that life sciences companies understand the trends and undercurrents of policy and practices being employed in order to succeed in these turbulent times. One key driver of these changes is the return to a primary care-driven model of care administration, delivered through the patient-centered medical home (PCMH).
PCMH Overview Executive Summary